Acalabrutinib, umbralisib \u0026 ublituximab (AU2) regimen in patients with de novo MCL

(2:2)

Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL

(1:27)

How CALQUENCE® (acalabrutinib) Works

(2:18)

CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD

(18:35)

Acalabrutinib Shows Promising Results for the Treatment of CLL

(1:46)

Acalabrutinib in patients with CLL and MCL undergoing alloSCT

(55)

Acalabrutinib for Treating Mantle Cell Lymphoma

(3:46)

Dr. Patel Discusses Promise of Acalabrutinib in MCL

(1:45)

Leukemia Patient Story: My 1st Symptoms for CLL | Stephen's Story (1/5) | The Patient Story

(10:30)

Acalabrutinib And Zanubrutinib in CLL

(19:32)

Acalabrutinib Versus Ibrutinib for CLL

(5:44)

Update on BTK inhibitors for CLL: Ibrutinib pus the new kids on the block: Are they better?

(21:42)

Understanding Chronic Lymphocytic Leukemia with Anthony Mato, MD

(8:43)

Roger talks about living with CLL

(13:49)

Understanding Follicular Lymphoma with Sarah Rutherford, MD

(13:46)

Lymphoproliferative Disorders

(52:6)

Update on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | LRF Webinars

(1:5:51)

CALQUENCE® (acalabrutinib) Patient Testimonials: Marialice’s Story

(4:33)

Understanding Chronic Lymphocytic Leukemia with Lindsey Roeker, MD

(11:15)

The safety and efficacy of acalabrutinib for the treatment of R/R MZL

(3:27)

Phase Ib/IIa study of AZD4573 + acalabrutinib in R/R DLBCL

(3:58)

Acalabrutinib and AZD9150 combination for the treatment of R/R DLBCL

(1:38)

Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia

(57)

Acalabrutinib from the patient's perspective

(16:16)

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

(1:40)

Adding umbralisib to ibrutinib produced responses in MCL, CLL

(37)

Dr. Mato on Ibrutinib Versus Acalabrutinib in CLL

(1:50)

First results of head-to-head acalabrutinib versus ibrutinib in CLL

(2:52)

Umbralisib and ublituximab in patients with CLL and comorbidities

(1:55)